NR4A1 and breast cancer: Because hormone receptor-negative breast cancers, including the HER2+ and triple-negative subtypes, are enriched in TAMs and have poor clinical outcomes [19, 20], the relative prognostic significance of elevated TAM infiltration in tumors of differing hormone receptor status needs to be evaluated.